BIOMAT Database Logo BIOMAT Database Logo

Diagnostic performance between in-house and commercial SARS-CoV-2 serological immunoassays including binding-specific antibody and surrogate virus neutralization test (sVNT). 2023

Poramed Winichakoon, and Jiraprapa Wipasa, and Kriangkrai Chawansuntati, and Parichat Salee, and Tavitiya Sudjaritruk, and Saowaluck Yasri, and Chantana Khamwan, and Rungnapa Peerakam, and Dararat Dankai, and Romanee Chaiwarith
Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.

This study aimed to evaluate the correlation between in-house and commercial binding-specific IgG antibodies and between in-house and commercial SARS-CoV-2 surrogate virus neutralization tests (sVNT). Samples from healthcare workers who received vaccines against SARS-CoV-2 were tested for RBD-specific antibody, S-specific antibody, and in-house ELISA, commercial sVNT, and in-house sVNT, against wild-type SARS-CoV-2. Three hundred and five samples were included in the analysis. The correlation between S-specific binding antibodies and in-house ELISA was 0.96 (95% CI 0.96-0.97) and between RBD-specific antibodies and in-house ELISA was 0.96 (95% CI 0.95-0.97). The Cohen's kappa between in-house sVNT and the commercial test was 0.90 (95% CI 0.80, 1.00). If using 90% inhibition of sVNT as the reference standard, the optimal cut-off value of RBD-specific antibodies was 442.7 BAU/mL, the kappa, sensitivity, and specificity being 0.99, 99%, and 100%, respectively. The optimal cut-off value of S-specific antibodies was 1155.9 BAU/mL, the kappa, sensitivity, and specificity being 0.99, 100%, and 99%, respectively. This study demonstrated a very strong correlation between in-house ELISA and 2 commercial assays. There was also a very strong correlation between in-house and commercial SARS-CoV-2 sVNT, a finding of particular interest which will inform future research.

UI MeSH Term Description Entries
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D007118 Immunoassay A technique using antibodies for identifying or quantifying a substance. Usually the substance being studied serves as antigen both in antibody production and in measurement of antibody by the test substance. Immunochromatographic Assay,Assay, Immunochromatographic,Assays, Immunochromatographic,Immunoassays,Immunochromatographic Assays
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000086382 COVID-19 A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent. 2019 Novel Coronavirus Disease,2019 Novel Coronavirus Infection,2019-nCoV Disease,2019-nCoV Infection,COVID-19 Pandemic,COVID-19 Pandemics,COVID-19 Virus Disease,COVID-19 Virus Infection,Coronavirus Disease 2019,Coronavirus Disease-19,SARS Coronavirus 2 Infection,SARS-CoV-2 Infection,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,COVID19,2019 nCoV Disease,2019 nCoV Infection,2019-nCoV Diseases,2019-nCoV Infections,COVID 19,COVID 19 Pandemic,COVID 19 Virus Disease,COVID 19 Virus Infection,COVID-19 Virus Diseases,COVID-19 Virus Infections,Coronavirus Disease 19,Disease 2019, Coronavirus,Disease, 2019-nCoV,Disease, COVID-19 Virus,Infection, 2019-nCoV,Infection, COVID-19 Virus,Infection, SARS-CoV-2,Pandemic, COVID-19,SARS CoV 2 Infection,SARS-CoV-2 Infections,Virus Disease, COVID-19,Virus Infection, COVID-19
D000086402 SARS-CoV-2 A species of BETACORONAVIRUS causing atypical respiratory disease (COVID-19) in humans. The organism was first identified in 2019 in Wuhan, China. The natural host is the Chinese intermediate horseshoe bat, RHINOLOPHUS affinis. 2019 Novel Coronavirus,COVID-19 Virus,COVID19 Virus,Coronavirus Disease 2019 Virus,SARS Coronavirus 2,SARS-CoV-2 Virus,Severe Acute Respiratory Syndrome Coronavirus 2,Wuhan Coronavirus,Wuhan Seafood Market Pneumonia Virus,2019-nCoV,2019 Novel Coronaviruses,COVID 19 Virus,COVID-19 Viruses,COVID19 Viruses,Coronavirus 2, SARS,Coronavirus, 2019 Novel,Coronavirus, Wuhan,Novel Coronavirus, 2019,SARS CoV 2 Virus,SARS-CoV-2 Viruses,Virus, COVID-19,Virus, COVID19,Virus, SARS-CoV-2,Viruses, COVID19
D000086663 COVID-19 Vaccines Vaccines or candidate vaccines containing SARS-CoV-2 component antigens, genetic materials, or inactivated SARS-CoV-2 virus, and designed to prevent COVID-19. 2019 Novel Coronavirus Vaccine,2019 Novel Coronavirus Vaccines,2019-nCoV Vaccine,2019-nCoV Vaccines,COVID 19 Vaccine,COVID-19 Vaccine,COVID-19 Virus Vaccine,COVID-19 Virus Vaccines,COVID19 Vaccine,COVID19 Vaccines,COVID19 Virus Vaccine,COVID19 Virus Vaccines,Coronavirus Disease 2019 Vaccine,Coronavirus Disease 2019 Vaccines,Coronavirus Disease 2019 Virus Vaccine,Coronavirus Disease 2019 Virus Vaccines,Coronavirus Disease-19 Vaccine,Coronavirus Disease-19 Vaccines,SARS Coronavirus 2 Vaccines,SARS-CoV-2 Vaccine,SARS-CoV-2 Vaccines,SARS2 Vaccine,SARS2 Vaccines,2019 nCoV Vaccine,2019 nCoV Vaccines,COVID 19 Vaccines,COVID 19 Virus Vaccine,COVID 19 Virus Vaccines,Coronavirus Disease 19 Vaccine,Coronavirus Disease 19 Vaccines,SARS CoV 2 Vaccine,SARS CoV 2 Vaccines,Vaccine, 2019-nCoV,Vaccine, COVID 19,Vaccine, COVID-19,Vaccine, COVID-19 Virus,Vaccine, COVID19,Vaccine, COVID19 Virus,Vaccine, Coronavirus Disease-19,Vaccine, SARS-CoV-2,Vaccine, SARS2,Vaccines, 2019-nCoV,Vaccines, COVID-19,Vaccines, COVID-19 Virus,Vaccines, COVID19,Vaccines, COVID19 Virus,Vaccines, Coronavirus Disease-19,Vaccines, SARS-CoV-2,Vaccines, SARS2,Virus Vaccine, COVID-19,Virus Vaccine, COVID19,Virus Vaccines, COVID-19,Virus Vaccines, COVID19
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies
D057134 Antibodies, Neutralizing Antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent, usually a virus. Neutralizing Antibodies,Antibody, Neutralizing,Neutralizing Antibody

Related Publications

Poramed Winichakoon, and Jiraprapa Wipasa, and Kriangkrai Chawansuntati, and Parichat Salee, and Tavitiya Sudjaritruk, and Saowaluck Yasri, and Chantana Khamwan, and Rungnapa Peerakam, and Dararat Dankai, and Romanee Chaiwarith
Validation and clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT).
December 2020, Emerging microbes & infections,
Poramed Winichakoon, and Jiraprapa Wipasa, and Kriangkrai Chawansuntati, and Parichat Salee, and Tavitiya Sudjaritruk, and Saowaluck Yasri, and Chantana Khamwan, and Rungnapa Peerakam, and Dararat Dankai, and Romanee Chaiwarith
Five Commercial Immunoassays for SARS-CoV-2 Antibody Determination and Their Comparison and Correlation with the Virus Neutralization Test.
March 2021, Diagnostics (Basel, Switzerland),
Poramed Winichakoon, and Jiraprapa Wipasa, and Kriangkrai Chawansuntati, and Parichat Salee, and Tavitiya Sudjaritruk, and Saowaluck Yasri, and Chantana Khamwan, and Rungnapa Peerakam, and Dararat Dankai, and Romanee Chaiwarith
Quantitative SARS-CoV-2 Spike Antibody Response in COVID-19 Patients Using Three Fully Automated Immunoassays and a Surrogate Virus Neutralization Test.
August 2021, Diagnostics (Basel, Switzerland),
Poramed Winichakoon, and Jiraprapa Wipasa, and Kriangkrai Chawansuntati, and Parichat Salee, and Tavitiya Sudjaritruk, and Saowaluck Yasri, and Chantana Khamwan, and Rungnapa Peerakam, and Dararat Dankai, and Romanee Chaiwarith
Evaluation of the correlation between the access SARS-CoV-2 IgM and IgG II antibody tests with the SARS-CoV-2 surrogate virus neutralization test.
January 2022, Journal of medical virology,
Poramed Winichakoon, and Jiraprapa Wipasa, and Kriangkrai Chawansuntati, and Parichat Salee, and Tavitiya Sudjaritruk, and Saowaluck Yasri, and Chantana Khamwan, and Rungnapa Peerakam, and Dararat Dankai, and Romanee Chaiwarith
Evaluation of residual humoral immune response against SARS-CoV-2 by a surrogate virus neutralization test (sVNT) 9 months after BNT162b2 primary vaccination.
June 2023, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy,
Poramed Winichakoon, and Jiraprapa Wipasa, and Kriangkrai Chawansuntati, and Parichat Salee, and Tavitiya Sudjaritruk, and Saowaluck Yasri, and Chantana Khamwan, and Rungnapa Peerakam, and Dararat Dankai, and Romanee Chaiwarith
Evaluation of a multi-species SARS-CoV-2 surrogate virus neutralization test.
December 2021, One health (Amsterdam, Netherlands),
Poramed Winichakoon, and Jiraprapa Wipasa, and Kriangkrai Chawansuntati, and Parichat Salee, and Tavitiya Sudjaritruk, and Saowaluck Yasri, and Chantana Khamwan, and Rungnapa Peerakam, and Dararat Dankai, and Romanee Chaiwarith
Comparison of commercial SARS-CoV-2 surrogate neutralization assays with a full virus endpoint dilution neutralization test in two different cohorts.
September 2022, Journal of virological methods,
Poramed Winichakoon, and Jiraprapa Wipasa, and Kriangkrai Chawansuntati, and Parichat Salee, and Tavitiya Sudjaritruk, and Saowaluck Yasri, and Chantana Khamwan, and Rungnapa Peerakam, and Dararat Dankai, and Romanee Chaiwarith
Detection of SARS-CoV-2 Antibodies: Comparison of Enzyme Immunoassay, Surrogate Neutralization and Virus Neutralization Test.
May 2023, Antibodies (Basel, Switzerland),
Poramed Winichakoon, and Jiraprapa Wipasa, and Kriangkrai Chawansuntati, and Parichat Salee, and Tavitiya Sudjaritruk, and Saowaluck Yasri, and Chantana Khamwan, and Rungnapa Peerakam, and Dararat Dankai, and Romanee Chaiwarith
Agreement between commercially available ELISA and in-house Luminex SARS-CoV-2 antibody immunoassays.
September 2021, Scientific reports,
Poramed Winichakoon, and Jiraprapa Wipasa, and Kriangkrai Chawansuntati, and Parichat Salee, and Tavitiya Sudjaritruk, and Saowaluck Yasri, and Chantana Khamwan, and Rungnapa Peerakam, and Dararat Dankai, and Romanee Chaiwarith
Reduced Binding between Omicron B.1.1.529 and the Human ACE2 Receptor in a Surrogate Virus Neutralization Test for SARS-CoV-2.
May 2023, Viruses,
Copied contents to your clipboard!